Incite Genomics
Incite Genomics is an Australian accredited genetic testing laboratory that provides pharmacogenomic tests — CNSDose, PredictAR™-pgx, Cardio-predict, and predictAR-plus — to clinicians, hospitals, laboratories, employers, and patients in Australia and the United States, guiding medication selection and dosing through evidence-based reporting.
- Company typePrivate
- Founded-
- HeadquartersBurwood East, Australia
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Incite Genomics does
Incite Genomics is an Australian, accredited genetic testing laboratory that provides pharmacogenomic (PGx) testing services to guide medication selection and dosing. The company operates from Melbourne, Victoria, as a subsidiary within the Incite Health group, and currently markets in Australia and the United States. Its core offering is a portfolio of PGx tests that analyze 18 genes — including drug metabolism genes (Phase I and Phase II), drug receptors and transporters, and — uniquely in CNSDose — blood-brain barrier genetics — to generate evidence-based medication and dosing recommendations anchored to CPIC, FDA, and Dutch Pharmacogenetics Working Group guidance.
The product suite comprises four tests: CNSDose, a mental health-focused panel for antidepressants and psychotropic medications; PredictAR™-pgx, a comprehensive report covering guidance for over 120 medications across cardiology, psychiatry, oncology, neurology, and other specialties; Cardio-predict, a cardiology panel targeting CYP2C19 variants for clopidogrel selection and SLCO1B1/ABCG2 for statin therapy; and predictAR-plus, an add-on that adds HLA markers to the PredictAR panel. Sample collection is supported via at-home cheek swab or blood-in-EDTA kits, with turnaround times of 2–9 business days depending on test. Reports are delivered through a secure cloud-based platform hosted on Australian servers.
Commercially, Incite runs a B2B sales motion targeting doctors, clinics, hospitals, and laboratories, supplemented by distribution agreements with Australian Clinical Labs (Australia) and Ethos Laboratories (US), and a coverage pathway via Medibank for eligible Australian members. Revenue mechanics combine one-time laboratory testing fees, laboratory technology-transfer partnerships (licensing/royalty-type), and a subscription/recurring component via the cloud-based reporting platform. Pricing is not publicly disclosed.
Incite Genomics firmographics
Firmographics- Name
- Incite Genomics
- Legal name
- Incite Genomics
- Website
- https://incitegenomics.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Incite Genomics is an Australian accredited genetic testing laboratory that provides pharmacogenomic tests — CNSDose, PredictAR™-pgx, Cardio-predict, and predictAR-plus — to clinicians, hospitals, laboratories, employers, and patients in Australia and the United States, guiding medication selection and dosing through evidence-based reporting.
- Ownership category
- akta.pro rank
Incite Genomics industry classification
Industry- Product category
- Pharmacogenomic Testing Services
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
- akta.pro secondary industries
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)
Keywords
Where Incite Genomics is headquartered
LocationHeadquarters
- HQ city
- Burwood East
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Incite Genomics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Pharmacogenomic Testing Services: One-time laboratory testing services providing pharmacogenomic reports to healthcare providers. Tests include CNSDose for mental health, PredictAR-pgx for comprehensive coverage, and Cardio-predict for cardiology. Results provided within 2-4 business days from sample receipt.
- Laboratory Technology Transfer: Partnerships with laboratories to implement Incite Genomics' proven genetic testing platform, including validation according to local accreditation guidelines.
- Cloud-based Reporting Platform: Secure cloud platform that intakes genomic data from partner laboratories and returns comprehensive clinical reports that are continuously updated as new evidence emerges.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based laboratory testing services |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
Incite Genomics product offering
Product offeringCore offering
Incite Genomics is an Australian accredited genetic testing laboratory that delivers pharmacogenomic testing services to guide medication selection and dosing for individual patients. Its core offering consists of three proprietary tests — CNSDose for mental health medications, PredictAR-pgx as a comprehensive multi-specialty panel covering 120+ medications, and Cardio-predict for cardiology — supported by a secure cloud-based reporting platform that produces continuously updated, evidence-based clinical reports.
Product overview
Incite Genomics offers a portfolio of pharmacogenomic tests designed to guide medication selection based on individual genetic profiles. The core product suite includes CNSDose (a mental health-focused test analyzing 18 genes including blood-brain barrier genetics for antidepressants and psychotropic medications), PredictAR™-pgx (a comprehensive expanded panel covering 120+ medications across multiple specialties), and Cardio-predict (a cardiology-focused test for Clopidogrel and statin therapy guidance). The add-on predictAR-plus extends the PredictAR panel with additional HLA markers. All tests provide evidence-based dosing recommendations and medication avoidance alerts derived from CPIC, FDA, and Dutch Pharmacogenetics Working Group guidelines. Sample collection options include cheek swabs and blood samples, with turnaround times of 2-9 business days depending on the test.
Differentiator
Problem solved
Functional benefit
Brands
- CNSDose: A proprietary genetic-based clinical support tool for psychotropic drugs, particularly relevant for antidepressants and mental health medications. Analyzes 18 genes including those impacting drug transportation to the brain via the blood-brain barrier.
- PredictAR™-pgx
- Cardio-predict
Products and services
- CNSDose A proprietary pharmacogenomic test designed for mental health medications that analyzes 18 genes — including blood-brain barrier genetics, liver metabolism genes (Phase I and Phase II), drug receptors, and transporters — to guide antidepressant and psychotropic medication and dose selection for clinicians. Provides medication dosing suggestions and avoidance alerts based on CPIC and Dutch Pharmacogenetics Working Group recommendations, covering more than 160 medications for psychiatrists, GPs, and mental health prescribers.
- PredictAR-pgx An expanded comprehensive pharmacogenomics report analyzing 18 genes to provide guidance for more than 120 medications across cardiology, psychiatry, oncology, neurology, and other specialties. Delivers evidence-based dosing suggestions and medication avoidance alerts derived from CPIC, FDA, and Dutch Pharmacogenetics Working Group recommendations, with a 3-4 business day turnaround time from sample receipt.
- Cardio-predict A cardiology-focused genetic test that detects loss-of-function CYP2C19 variants to guide antiplatelet therapy (Clopidogrel) selection and analyzes SLCO1B1 and ABCG2 variants to guide statin therapy and assess risk of statin-related muscle pain. Targets CYP2C19, SLCO1B1, and ABCG2 genes for cardiologists and prescribing clinicians, with reports available within 2-3 business days.
- Laboratory Technology Transfer and Cloud Reporting Platform A licensing and technology transfer offering for partner laboratories worldwide that want to establish pharmacogenomic testing capabilities or generate comprehensive, continuously updated clinical reports from their existing genomic data. Includes technology validation aligned with local accreditation guidelines and access to the secure cloud-based platform that intakes genomic data and returns continuously updated clinical reports.
Quantifiable outcome
- Up to 30% reduction in unwanted adverse drug reactions
- +2 more outcomes
Companies that use Incite Genomics
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles5 records
Incite Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Incite Genomics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Australian Clinical LabscoreDistribution agreement signed with Australian Clinical Labs (ACL) for CNSDose testing. This partnership marks an important step in expanding access to CNSDose testing across Australia. Through ACL's national network, CNSDose will be more readily available to clinicians supporting patients with mental health conditions nationwide.
- Ethos LaboratoriescorePartnership with US-based Ethos Laboratories to make the CNSDose mental health PGx test available in the US market. This represents Incite Genomics' expansion into the US healthcare market.
- MedibankminorAustralian Medibank members with Mental Health Support included on their cover may be eligible for a rebate towards CNSDose pharmacogenetic testing. This partnership provides insurance coverage pathway for eligible members.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
Incite Genomics competitors and assessment
Company assessmentBroad incumbents
- Quest Diagnostics: Largest US clinical laboratory offering PGx testing among its broader diagnostics menu. Reaches the same primary care and specialist prescriber base Incite targets, with significant advantages in payor contracts and EHR integration.
- GeneDx: Clinical genomics company offering a broad menu including pharmacogenomics and rare disease diagnostics. Public under Nasdaq and well-funded, competing for the same physician and hospital genomic testing budgets.
- Laboratory Corporation of America (Labcorp): Global clinical laboratory network with pharmacogenomic testing as part of its service menu. Reaches ordering physicians across primary care, cardiology, and psychiatry — overlapping directly with Incite's provider segments.
Direct peers
- Genomind: US-based PGx company specializing in mental health pharmacogenomics (Genecept Assay). Most direct competitor to CNSDose, serving psychiatrists and behavioral health clinicians with similar gene panel-based dosing guidance for psychotropic medications.
- Myriad Genetics: Acquired Assurex Health (GeneSight), the leading psychiatric PGx test in the US. Most established incumbent in the mental health PGx category that CNSDose targets, with strong psychiatric provider penetration.
- Color Health: Offers comprehensive genetic testing including PGx panels across multiple therapeutic areas. Provides at-home sample collection and B2B employer/payer channels — directly comparable to Incite's distribution model and product breadth.
- Admera Health: Specialized PGx and clinical genomics laboratory offering comprehensive panels serving physicians, hospitals, and employers. Closely comparable in product profile (multi-specialty PGx) and laboratory service model.
Regional players
- Sonic Healthcare: Parent company of Australian Clinical Labs (Incite's AU distribution partner). While not a direct seller of competing PGx tests in Australia, the structural relationship makes Sonic a strategically important peer shaping channel access and competitive dynamics in Australia.
Emerging players
- 23andMe: Consumer-focused genetic testing provider with growing pharmacogenomic content in its health reports. Comparable as a competing entry point for genetic data in medication selection, though less clinical-decision-focused than Incite.
- Genomic Testing Cooperative: Specialized genomics laboratory providing comprehensive pharmacogenomics and clinical interpretation services, often through hospital and academic medical center partnerships. Comparable technology transfer and B2B laboratory model to Incite's licensing offerings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Incite Genomics social profiles
Digital presenceIncite Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Incite Genomics leadership team
Management profileNumber of profiles
Incite Genomics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Incite Genomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Incite Genomics
What does Incite Genomics do?
Incite Genomics is an Australian accredited genetic testing laboratory that delivers pharmacogenomic testing services to guide medication selection and dosing for individual patients. Its core offering consists of three proprietary tests — CNSDose for mental health medications, PredictAR-pgx as a comprehensive multi-specialty panel covering 120+ medications, and Cardio-predict for cardiology — supported by a secure cloud-based reporting platform that produces continuously updated, evidence-based clinical reports.
Is Incite Genomics a public or private company?
Incite Genomics is a private company. It is classified as corporate owned and is currently operating.
When was Incite Genomics founded?
Incite Genomics was founded in -1. It employs 1 to 10 people.
Where is Incite Genomics based?
Incite Genomics is headquartered in Burwood East, Australia, in the Oceania region.
How does Incite Genomics make money?
Three revenue lines are on record. Pharmacogenomic Testing Services are the primary driver. The others are laboratory Technology Transfer and cloud-based Reporting Platform.
Who are Incite Genomics's main competitors?
Broad incumbents on record are Quest Diagnostics, GeneDx and Laboratory Corporation of America (Labcorp). Direct peers are Genomind, Myriad Genetics, Color Health and Admera Health. Sonic Healthcare is listed as a regional player. Emerging players are 23andMe and Genomic Testing Cooperative.
Does Incite Genomics have an API?
No public API is recorded for Incite Genomics.
What industry is Incite Genomics in?
Incite Genomics's product category is Pharmacogenomic Testing Services. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 621511 and its SIC code is 2835.